These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 14526768)

  • 1. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Hull JH; Hull PJ
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526768
    [No Abstract]   [Full Text] [Related]  

  • 2. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Kaufman JL
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526769
    [No Abstract]   [Full Text] [Related]  

  • 3. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Nader F
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526767
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Blot E; Gutman F; Thannberger A
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14523150
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?
    Prescrire Int; 2000 Feb; 9(45):197-8. PubMed ID: 11503794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated thrombosis.
    Bick RL
    N Engl J Med; 2003 Jul; 349(2):109-11. PubMed ID: 12853582
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
    J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing venous thromboembolism, especially in elderly people.
    Le Gal G; Mottier D
    Arch Intern Med; 2005 Dec 12-26; 165(22):2687. PubMed ID: 16344430
    [No Abstract]   [Full Text] [Related]  

  • 12. Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers.
    Ferguson RE; Critchfield A; Leclaire A; Ajkay N; Vasconez HC
    Burns; 2005 Dec; 31(8):964-6. PubMed ID: 16269216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
    Levine M
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices.
    Lee AY
    Dis Mon; 2005; 51(2-3):150-7. PubMed ID: 15900267
    [No Abstract]   [Full Text] [Related]  

  • 16. What's new for DVT prophylaxis for the medically ill.
    Ageno W; Turpie AG
    Dis Mon; 2005; 51(2-3):194-9. PubMed ID: 15900272
    [No Abstract]   [Full Text] [Related]  

  • 17. Dalteparin and heparin-induced thrombocytopenia.
    Davidson BL
    N Engl J Med; 2011 Sep; 365(12):1158; author reply 1158. PubMed ID: 21992138
    [No Abstract]   [Full Text] [Related]  

  • 18. Arterial and venous disease and deep vein thrombosis. Injecting drug use is major risk factor for deep vein thrombosis.
    Baldeweg SE
    BMJ; 2000 Oct; 321(7267):1018. PubMed ID: 11039983
    [No Abstract]   [Full Text] [Related]  

  • 19. Dalteparin in critically ill patients.
    Esterbrook G; Hart S
    N Engl J Med; 2011 Jul; 365(2):179; author reply 180. PubMed ID: 21751920
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
    Lapidus LJ; Rosfors S; Ponzer S; Levander C; Elvin A; Lärfars G; de Bri E
    J Orthop Trauma; 2007 Jan; 21(1):52-7. PubMed ID: 17211270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.